A Clinical Study Assessing Efficacy of an Herbal Blend on Menopausal Symptoms and Quality of Life

NCT ID: NCT04228757

Last Updated: 2020-02-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

130 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-06-28

Study Completion Date

2020-04-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This 12-week study is a randomized, placebo-controlled study assessing the efficacy of an herbal blend on menopausal symptoms and quality of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to evaluate changes in menopause symptoms after taking an herbal supplement daily for 12 weeks compared to placebo (a tablet that does not have active ingredients). This is a remote study, meaning all study data will be collected via the ClaimIt app, with the exception of a screening lab appointment and a Week 12 lab appointment.Participants will be asked to report on study compliance and respond to a series of questionnaires relating to symptoms of menopause, hot flashes, and quality of life.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Menopause

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, double-blind, placebo-controlled intervention
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators
A unique ID number will be assigned by ClaimIt to each enrolled subject and associated with the correct study product kit number; this number will be used throughout the study. Both the study product and placebo will be labeled identically except for kit number and will be distinguishable only by the individual participant ID and kit number.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Investigational Herbal Blend

A phytoestrogen herbal blend

Group Type EXPERIMENTAL

phytoestrogen herbal blend

Intervention Type DIETARY_SUPPLEMENT

phytoestrogen herbal blend

Placebo

Tablet without active ingredients

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Tablet without active ingredients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

phytoestrogen herbal blend

phytoestrogen herbal blend

Intervention Type DIETARY_SUPPLEMENT

Placebo

Tablet without active ingredients

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Females between 40 and 65 years of age
* Report experiencing moderate to severe menopausal symptoms, characterized as including all of the following:

* Total Score of 11 or greater on the Greene Climacteric Scale (GCS) Questionnaire
* Self-reported frequent hot flashes experienced (estimated minimum of 28 during the past week, or an average of a minimum of 4 in a typical day)
* Absence of a regular menstrual cycle, defined as either: an irregular cycle for at least 6 months, or the absence of menses for 3 or more months
* Agreement to maintain current level of physical activity throughout the study period
* Willingness and ability to follow the procedures of the study
* Willingness and ability to provide informed consent

Exclusion Criteria

* Participant with a Body Mass Index (BMI) ≥ 30mg/kg2
* Participant who has had both ovaries removed
* Women who are pregnant, breastfeeding, or planning on becoming pregnant during the course of the study
* A history of breast cancer or a positive mammogram
* A history of uterine cancer or an abnormal pap smear
* Abnormal vaginal bleeding (not related to menstrual irregularity)
* Liver disease
* A history of clinically diagnosed depression that a medical professional recommended should be medically treated
* A history of clinically diagnosed hypertension (systolic of 140 mmHg or greater or diastolic of 90 mmHg or greater)
* Hyperthyroidism determined by thyroid stimulating hormone (TSH) screening
* Any unstable medical condition as determined by the Principal Investigator (PI)
* Any significant clinical or laboratory abnormality identified by the PI
* Any change in the use of dietary supplements in the 2-month prior to enrollment
* The use of any product indicated for menopause symptoms in the 2 months prior to enrollment including: prescription drugs (e.g. estrogen/progestins), over-the-counter supplements (e.g. black cohosh, soy isoflavones, evening primrose oil, phytoestrogens, etc), or a significant change in diet to include more soy foods.
* The use of any psychiatric drugs in the 6 months prior to enrolling
* Self-reported abuse of drugs or alcohol
* Any smoking of cigarettes, vaping or e-cigarettes, or consumption of other tobacco products within the past 6 months
* Planned donation of blood during or up to 30 days after completion of the study
* An allergy to any ingredient in the herbal blend product or placebo
* A sensitivity to botanical extracts
* Previous participation in a clinical research study less than 30 days prior to randomization to a treatment group
* Any other condition that in the investigator's opinion may adversely affect the participant's ability to complete the study, or may pose a significant risk to the participant
Minimum Eligible Age

40 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ObvioHealth

INDUSTRY

Sponsor Role collaborator

i-Health, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Parth Shah, MD

Role: PRINCIPAL_INVESTIGATOR

ObvioHealth

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

ObvioHealth

Orlando, Florida, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Utian WH, Archer DF, Bachmann GA, Gallagher C, Grodstein Fn, Heiman JR, Henderson VW, Hodis HN, Karas RH, Lobo RA, Manson JE, Reid RL, Schmidt PJ, Stuenkel CA; North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause. 2008 Jul-Aug;15(4 Pt 1):584-602. doi: 10.1097/gme.0b013e31817b076a.

Reference Type BACKGROUND
PMID: 18580541 (View on PubMed)

Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G; WHI Investigators. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 2009 Feb 5;360(6):573-87. doi: 10.1056/NEJMoa0807684.

Reference Type BACKGROUND
PMID: 19196674 (View on PubMed)

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321-33. doi: 10.1001/jama.288.3.321.

Reference Type BACKGROUND
PMID: 12117397 (View on PubMed)

Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev. 2013 Dec 10;2013(12):CD001395. doi: 10.1002/14651858.CD001395.pub4.

Reference Type BACKGROUND
PMID: 24323914 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OBVIO-DSM-003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Qing'E Formula Therapy on Menopausal Symptoms
NCT01805765 COMPLETED PHASE2/PHASE3